ICU Medical ICUI
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
ICU Medical (ICUI) Business Model and Operations Summary
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.
Key Insights
ICU Medical (ICUI) Core Market Data and Business Metrics
Latest Closing Price
$137.8Market Cap
$3.40 BillionPrice-Earnings Ratio
-28.53Total Outstanding Shares
24.52 Million SharesTotal Employees
15,000Dividend
No dividendIPO Date
March 31, 1992SIC Description
Surgical & Medical Instruments & ApparatusPrimary Exchange
NASDAQHeadquarters
951 Calle Amanecer, San Clemente, CA, 92763-6212
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow | $54.34 Million |
| Net Cash Flow From Investing Activities | $-88.96 Million |
| Net Cash Flow From Operating Activities, Continuing | $204.03 Million |
| Net Cash Flow From Financing Activities, Continuing | $-55.80 Million |
| Net Cash Flow From Investing Activities, Continuing | $-88.96 Million |
| Net Cash Flow From Operating Activities | $204.03 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Interest And Dividend Income, Operating | $10.79 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
| Income Tax Expense/Benefit | $51.68 Million |
| Interest Expense, Operating | $106.54 Million |
| Diluted Earnings Per Share | $-4.83 |
| Net Income/Loss Attributable To Parent | $-117.69 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss | $-204.01 Million |
| Other Comprehensive Income/Loss | $-86.32 Million |
| Comprehensive Income/Loss Attributable To Parent | $-204.01 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Cash | $308.57 Million |
| Commitments and Contingencies | $0 |
| Inventory | $584.68 Million |
| Liabilities | $2.24 Billion |
| Equity Attributable To Noncontrolling Interest | $0 |
| Fixed Assets | $442.75 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||